HOPSCOTCH GROUPE : Agenda financier 2025
Communiqué de presse Paris, le 18 avril 2025, 16h HOPSCOTCH GROUPEAgenda Financier 2025 HOPSCOTCH (Euronext Growth FR0000065278), Groupe de conseil en communication, acteur majeur du digital, des relations publics et…
LVMH: 2024 Dividend
Paris, Friday, April 18th, 2025 At the Annual Shareholders’ Meeting of LVMH Moët Hennessy Louis Vuitton held on Thursday, April 17th, 2025, approval was given for the payment of a…
Bolloré – Press release
BOLLORÉ PRESS RELEASE April 17, 2025 On September 13, 2024, Bolloré SE had filed three alternative buyout offers followed by mandatory squeeze-outs on the shares of Compagnie du Cambodge, Financière…
LVMH : Dividende 2024
Paris, le vendredi 18 avril 2025 L’Assemblée Générale de LVMH Moët Hennessy Louis Vuitton, réunie le jeudi 17 avril 2025 a approuvé, au titre de l’exercice 2024, le paiement d’un…
Christian Dior: 2024 Dividend
Paris, April 18th, 2025 2024 DIVIDEND At the Annual Shareholders’ Meeting of Christian Dior held on Thursday, April 17th, 2025, approval was given for the payment of a dividend for…
Christian Dior : Dividende 2024
Paris, le 18 avril 2025 DIVIDENDE 2024 L’Assemblée Générale de Christian Dior, réunie le jeudi 17 avril 2025, a approuvé au titre de l’exercice 2024 le paiement d’un dividende de…
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years…
Correction: Communiqué du Groupe Bolloré
BOLLORÉ COMMUNIQUÉ DE PRESSE Le 17 avril 2025 Bolloré SE avait déposé le 13 septembre 2024 trois offres publiques de retrait alternatives suivies d’un retrait obligatoire visant les actions de…
Correction: Bolloré – Press release
BOLLORÉ PRESS RELEASE April 17, 2025 On September 13, 2024, Bolloré SE had filed three alternative buyout offers followed by mandatory squeeze-outs on the shares of Compagnie du Cambodge, Financière…
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch…